CNTAHIGH SIGNALRISK10-K

CNTA entered into a transaction agreement with Eli Lilly on March 31, 2026, while experiencing severe cash burn with cash equivalents plummeting 84% to $61.3M amid worsening operating losses.

The transaction agreement with Eli Lilly represents a material corporate development that could fundamentally alter CNTA's structure, likely indicating a potential acquisition or strategic partnership given the company's deteriorating financial position. The dramatic 84% decline in cash reserves combined with worsening operating cash flow burn rate signals potential liquidity concerns that may have driven this strategic transaction.

Comparing 2026-03-31 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

CNTA's financial position deteriorated significantly with cash equivalents collapsing 84% to $61.3M while operating cash flow burn worsened 36% to -$193.8M, indicating severe liquidity pressure. Despite this cash drain, stockholders' equity increased 31% to $526.9M and net losses improved 16%, suggesting potential injection of capital or non-cash adjustments possibly related to the Eli Lilly transaction. The overall picture shows a company facing critical cash constraints that likely necessitated the strategic transaction announced in March 2026.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+991.2%
$34K→$371K

Capital expenditure jumped 991.2% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
-84%
$383.2M→$61.3M

Cash declined 84% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-36.4%
-$142.1M→-$193.8M

Operating cash flow fell 36.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+36.1%
$7.3M→$9.9M

Interest expense surged 36.1% — significant debt increase or rising rates materially impacting earnings.

Current Assets
Balance Sheet
-31.4%
$536.4M→$367.9M

Current assets declined 31.4% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
+31.2%
$401.5M→$526.9M

Equity base grew 31.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-26%
$58.0M→$42.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
+19.2%
$576.8M→$687.5M

Asset base grew 19.2% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
+16.2%
-$235.8M→-$197.5M

Net income grew 16.2% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-24
ADDED
The registrant had outstandi ng 154,568,531 ordinary shares as of March 17, 2026.
Auditor Firm Id: 185 Auditor Name: KPMG LLP Auditor Location: Boston, Massachusetts Summary of the Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business.
These risks are described more fully in Item 1A - Risk Factors, and include, but are not limited to, the following: the Transaction Agreement we entered into on March 31, 2026 with Eli Lilly and Company and LDH XV Corporation, and the risks and uncertainties and potential impacts and timing relating thereto; We may not be successful in our efforts to build a pipeline of product candidates with commercial value.
We have incurred net losses since inception, and we expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability.
Our product candidates are in various stages of development, including several in discovery, preclinical, and clinical stages, and may fail in development or suffer delays that materially adversely affect their commercial viability and we may fail to differentiate our molecules, including cleminorexton, ORX142, ORX489 and other orexin agonist molecules from other available treatment options including other molecules in development.
+7 more — sign up free →
REMOVED
The registrant had outstandi ng 133,184,349 ordinary shares as of March 10, 2025.
Summary of the Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business.
These risks are described more fully in Item 1A - Risk Factors, and include, but are not limited to, the following: We may not be successful in our efforts to use our differentiated asset-centric approach to drug discovery and development to build a pipeline of product candidates with commercial value.
We, and our Centessa Subsidiaries, have incurred net losses since inception, and we expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability.
Our product candidates are in various stages of development, including several in discovery and preclinical stages, and may fail in development or suffer delays that materially adversely affect their commercial viability and we may fail to differentiate our molecules, including ORX750, ORX142, ORX489 and other orexin agonist molecules, other LockBody molecules and/or the LockBody technology platform from other available treatment options including other molecules in development.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →